Skip to main content

Table 2 Univariate Cox analysis of clinical variables and molecular markers for tamoxifen-treated patients (cohort-1)

From: Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Variable

0 to 10 years DEFS

 

0 to 5 years DEFS

 

5 to 10 years DEFS

 
 

Hazard ratio (95% CI)

P a

P b

Hazard ratio (95% CI)

P a

P b

Hazard ratio (95% CI)

P a

P b

Age

1.02 (1.00, 1.04)

0.021

0.657

1.02 (0.99, 1.04)

0.153

0.214

1.04 (1.00, 1.08)

0.042

0.168

Stage T2/3 vs T1

2.71 (1.76, 4.19)

<0.0001

0.581

2.51 (1.47, 4.26)

0.0007

0.211

3.14 (1.49, 6.64)

0.003

0.164

Node-positive vs -negative

2.47 (1.75, 3.48)

<0.0001

0.964

2.51 (1.65, 3.82)

<0.0001

0.732

2.67 (1.44, 4.97)

0.002

0.941

Grade

         

   Intermediate vs low

2.19 (1.20, 3.99)

0.011

0.11

3.97 (1.57, 9.99)

0.003

0.175

1.04 (0.44, 2.45)

0.934

0.192

   High vs low

2.96 (1.56, 5.62)

0.0009

5.05 (1.92, 13.3)

0.001

1.66 (0.67, 4.12)

0.277

HER2-positive vs -negative

2.64 (1.43, 4.90)

0.002

0.029

3.68 (1.91, 7.10)

0.0001

0.369

0.72 (0.11, 5.26)

0.75

0.141

High MKS vs low MKS

2.96 (2.07, 4.25)

<0.0001

0.04

3.89 (2.42, 6.24)

<0.0001

0.473

1.90 (1.04, 3.46)

0.036

0.377

Low ERS vs high ERS

2.00 (1.41, 2.83)

<0.0001

0.0008

3.26 (2.04, 5.19)

<0.0001

0.091

0.91 (0.50, 1.66)

0.763

0.728

MKS/ERS combined groups

         

   LowMKS/lowERS vs lowMKS/highERS

2.37 (1.29, 4.35)

0.005

<0.0001

1.98 (0.87, 4.51)

0.104

0.285

3.36 (1.29, 8.73)

0.013

0.862

   HighMKS/highERS vs lowMKS/highERS

3.66 (2.04, 6.57)

<0.0001

2.46 (1.09, 5.54)

0.029

6.59 (2.62, 16.6)

<0.0001

   HighMKS/lowERS vs lowMKS/highERS

5.35 (3.12, 9.17)

<0.0001

7.78 (3.97, 15.3)

<0.0001

1.46 (0.45, 4.79)

0.531

Other genomic signatures

         

High GGI vs low GGI

2.73 (1.94, 3.86)

<0.0001

0.005

3.81 (2.43, 5.97)

<0.0001

0.296

1.64 (0.90, 2.99)

0.109

0.02

Mammaprint poor vs good

2.93 (1.91, 4.49)

<0.0001

0.22

3.59 (2.02, 6.30)

<0.0001

0.768

2.30 (1.16, 4.56)

0.017

0.184

Three-gene model SCMGENE

         

   ER+/HER2-highP vs ER+/HER2-lowP

2.13 (1.47, 3.08)

<0.0001

0.017

2.58 (1.59, 4.18)

0.0001

0.585

1.60 (0.87, 2.95)

0.127

0.197

   HER2+ vs ER+/HER2-lowP

4.06 (2.09, 7.86)

<0.0001

6.63 (3.17, 13.9)

<0.0001

0.89 (0.12, 6.64)

0.909

   ER-/HER2- vs ER+/HER2-lowP

2.55 (1.01, 6.42)

0.048

4.70 (1.79, 12.3)

0.002

NA

 

PAM50

         

   LumB vs lumA

3.01 (2.01, 4.51)

<0.0001

0.004

3.84 (2.21, 6.65)

<0.0001

0.109

2.26 (1.20, 4.24)

0.011

0.147

   HER2 vs lumA

8.88 (4.36, 18.1)

<0.0001

14.4 (6.37, 32.8)

<0.0001

2.37 (0.31, 17.9)

0.403

   Basal vs lumA

3.03 (1.07, 8.58)

0.036

 

6.48 (2.17, 19.4)

0.0008

 

NA

  
  1. aP-value generated by univariate Cox analysis. bP-value for the test of the proportional hazard assumption based on the scaled Schoenfeld residuals. P-values in boldface were statistically significant at P<0.05. DEFS, distant event-free survival; MKS, mitotic kinase score; ERS, estrogen-related score; GGI, genomic grade index; Lum, luminal; ER+/HER2-lowP, ER-positive/human epidermal growth factor receptor 2 (HER2)-negative low proliferation; ER+/HER2-highP, ER-positive/HER2-negative high proliferation; NA, not applicable.